Skip to main content

Peer Review reports

From: Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study

Original Submission
27 Sep 2023 Submitted Original manuscript
4 Nov 2023 Reviewed Reviewer Report - Mahmut Emre Yildirim
12 Nov 2023 Reviewed Reviewer Report
20 Nov 2023 Author responded Author comments - Xiaobing Chen
22 Nov 2023 Author responded Author comments - Xiaobing Chen
Resubmission - Version 2
20 Nov 2023 Submitted Manuscript version 2
8 Dec 2023 Reviewed Reviewer Report
Resubmission - Version 3
Submitted Manuscript version 3
Publishing
9 Dec 2023 Editorially accepted
15 Dec 2023 Article published 10.1186/s12885-023-11735-z

You can find further information about peer review here.

Back to article page